Ísrael - enska - Ministry of Health

eli lilly israel ltd - insulin lispro; insulin lispro as protamine - suspension for injection - insulin lispro 25 %; insulin lispro as protamine 75 % - insulin lispro - insulin lispro - humalog mix 25 kwikpen is indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Ísrael - enska - Ministry of Health

eli lilly israel ltd, israel - insulin lispro; insulin lispro as protamine - suspension for injection - insulin lispro 50 %; insulin lispro as protamine 50 % - insulin lispro - insulin lispro - humalog mix 50 kwikpen is indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: glycerol; phenol; metacresol; zinc; dibasic sodium phosphate dihydrate; arginine; hydrochloric acid; sodium hydroxide; water for injections; nicotinamide - treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: glycerol; phenol; metacresol; zinc; dibasic sodium phosphate dihydrate; arginine; hydrochloric acid; sodium hydroxide; water for injections; nicotinamide - treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: glycerol; phenol; metacresol; zinc; dibasic sodium phosphate dihydrate; arginine; hydrochloric acid; sodium hydroxide; water for injections; nicotinamide - treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin detemir, quantity: 100 u/ml - injection, solution - excipient ingredients: glycerol; sodium hydroxide; dibasic sodium phosphate dihydrate; water for injections; hydrochloric acid; zinc acetate; metacresol; phenol; sodium chloride - treatment of diabetes mellitus. (see 'pharmacology' and 'clinical trials.')

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin detemir, quantity: 100 u/ml - injection, solution - excipient ingredients: phenol; glycerol; dibasic sodium phosphate dihydrate; metacresol; hydrochloric acid; zinc acetate; water for injections; sodium hydroxide; sodium chloride - treatment of diabetes mellitus. (see 'pharmacology' and 'clinical trials.')

Ísrael - enska - Ministry of Health

novo nordisk ltd., israel - insulin aspart - suspension for injection - insulin aspart 100 u/ml - insulin aspart - insulin aspart - novomix® 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above. משטר מינון : 7/8/2019posology and method of administrationposologythe potency of insulin analogues, including insulin aspart, is expressed in units, whereas the potency of human insulin is expressed in international units.novomix ®30 dosing is individual and determined in accordance with the needs of the patient. blood glucose monitoring and insulin dose adjustments are recommended to achieve optimal glycaemic control.in patients with type 2 diabetes, novomix® 30 can be given as monotherapy. novomix® 30 can also be given in combination with oral antidiabetic medicinal products and/or glp-1 receptor agonists . for patients with type 2 diabetes, the recommended starting dose of novomix® 30 is 6 units at breakfast and 6 units at dinner (evening meal). novomix® 30 can also be initiated once daily with 12 units at dinner (evening meal). when using novomix® 30 once daily, it is generally recommended to move to twice daily when reaching 30 units by splitting the dose into equal breakfast and dinner doses. if twice daily dosing with novomix ®30 results in recurrent daytime hypoglycaemic episodes, the morning dose can be split into morning and lunchtime doses (thrice daily dosing).the following titration guideline is recommended for dose adjustments:pre-meal blood glucose level novomix® 30 dose adjustment<4.4 mmol/l <80 mg/dl -2 units4.4–6.1 mmol/l 80–110 mg/dl 06.2–7.8 mmol/l 111–140 mg/dl +2 units7.9–10 mmol/l 141–180 mg/dl +4 units>10 mmol/l >180 mg/dl +6 unitsthe lowest of the three previous days’ pre-meal blood glucose levels should be used. the dose should not be increased if hypoglycaemia occurred within these days. dose adjustments can be made once a week until target hba1c is reached. pre-meal blood glucose levels should be used to evaluate the adequacy of the preceding dose.in patients with type 2 diabetes, a dose reduction of 20% is recommended for patients with an hba1c less than 8% when a glp-1 receptor agonist is added to novomix 30, to minimise the risk of hypoglycaemia. for patients with an hba1c higher than 8% a dose reduction should be considered. subsequently, dosage should be adjusted individually.

Ísrael - enska - Ministry of Health

sanofi israel ltd - insulin glargine; lixisenatide - solution for injection - lixisenatide 33 mcg / 1 ml; insulin glargine 100 units / 1 ml - insulin glargine - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sodium-glucose co-transporter-2 (sglt-2) inhibitors

Ísrael - enska - Ministry of Health

sanofi israel ltd - insulin glargine; lixisenatide - solution for injection - lixisenatide 50 mcg / 1 ml; insulin glargine 100 units / 1 ml - insulin glargine - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sodium-glucose co-transporter-2 (sglt-2) inhibitors.